Clinical trials: Castrate-resistant Prostate Cancer
Metastatic Castration Resistant Prostate Cancer
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
The purpose of this study is to provide real world data on treatment with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients.
- Trial name
- NCT03328364
- Testing
- enzalutamide, docetaxel
- Where
- Sweden
- Volunteers
- 211 people
- Sponsor
- Astellas Pharma a/s
Prostate Cancer
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed…
- Trial name
- NCT01193257
- Testing
- Orteronel, Prednisone
- Where
- 78 sites in United States, Australia and 12 more
- Volunteers
- 1,099 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer Metastatic
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This study will test the safety and efficacy of FOR46 given every 21 days to patients with metastatic castration-resistant prostate cancer. The name of the study drug involved in this study is: FOR46 for Injection (FOR46)
- Trial name
- NCT03575819
- Testing
- FOR46
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Fortis Therapeutics, Inc.
Metastatic Castration-resistant Prostate Cancer
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.
- Trial name
- NCT06383052
- Testing
- 177Lu-NYM032 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Norroy Bioscience Co., LTD
Prostate Cancer
Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer
- Trial name
- NCT05973149
- Testing
- QLH12016
- Where
- 2 sites in China
- Volunteers
- 108 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Non-metastatic Castration-resistant Prostate Cancer
An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
This is an observational study in which patient data from the past on men with non-metastatic castration-resistant prostate cancer are studied.
- Trial name
- DEAR (NCT05362149)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
- Where
- United States
- Volunteers
- 870 people
- Sponsor
- Bayer
Prostate Cancer
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
This Phase 3 study has been designed to confirm that adding custirsen to cabazitaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard cabazitaxel/prednisone treatment in men with…
- Trial name
- AFFINITY (NCT01578655)
- Testing
- cabazitaxel, prednisone, custirsen sodium
- Where
- 94 sites in United States, Australia and 6 more
- Volunteers
- 630 people
- Sponsor
- Achieve Life Sciences
Metastatic Castration-resistant Prostate Cancer
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Trial name
- NCT04556617
- Testing
- PLX2853 20 mg, Olaparib, Abiraterone acetate
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Opna Bio LLC
Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
The study consists of Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, sequential cohorts of subjects will receive escalating doses of ITC-6146RO to determine maximum tolerated dose (MTD) and/or optimal…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Metastatic Solid Tumor
- Trial name
- NCT07423117
- Testing
- ITC-6146RO
- Where
- 3 sites in South Korea
- Volunteers
- 102 people
- Sponsor
- IntoCell, Inc
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Prostate Cancer
A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer
The purpose of this clinical study is to assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer
- Trial name
- NCT00644488
- Testing
- BMS-641988 (AR#2)
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Castration-resistant Prostate Cancer, Metastatic Breast Cancer
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
The purpose of this first multi-dose study in cancer patients is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D), characterize the safety, tolerability and pharmacokinetics profile.
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Breast Cancer, Uterine Leiomyoma
- Trial name
- NCT01338831
- Testing
- LFA102
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumours
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
- Trial name
- NCT04564027
- Testing
- Ceralasertib
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
To evaluate the safety and efficacy (Overall survival [OS]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.
- Trial name
- NCT01810770
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 27 sites in China, Singapore and 2 more
- Volunteers
- 243 people
- Sponsor
- Bayer
Prostate Cancer, Tumors
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
To determine the feasibility and safety of administering YM155 in combination with docetaxel
- Trial name
- NCT00514267
- Testing
- YM 155, Docetaxel, Prednisone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Astellas Pharma Inc
Metastatic Castration-Resistant Prostate Cancer Patients
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
The study seek to evaluate the anti-tumor effect after treatment of Irofulven in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic…
- Trial name
- NCT03643107
- Testing
- Irofulven, Prednisolone 10 mg
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Allarity Therapeutics
Castration Resistant Prostate Cancer
Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.
- Trial name
- NCT01540071
- Testing
- NRX 194204
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Io Therapeutics
Prostate Cancer
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer.
- Trial name
- Mainsail (NCT00988208)
- Testing
- Lenalidomide, Docetaxel, Prednisone
- Where
- 210 sites in United States, Australia and 19 more
- Volunteers
- 1,059 people
- Sponsor
- Celgene
Cancer, Metastatic Castration-resistant Prostate Cancer
Study of INKmune in Patients With mCRPC (CaRe Prostate)
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart.
- Conditions
- Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
- Trial name
- CaRe (NCT06056791)
- Testing
- INKmune
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Inmune Bio, Inc.